| 000 | 01043 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250517083607.0 | ||
| 264 | 0 | _c20160608 | |
| 008 | 201606s 0 0 eng d | ||
| 022 | _a1474-547X | ||
| 024 | 7 |
_a10.1016/S0140-6736(16)00654-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNetto, George J | |
| 245 | 0 | 0 |
_aRole for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cMay 2016 |
||
| 300 |
_a1881-2 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aB7-H1 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aUrologic Neoplasms _xdrug therapy |
| 773 | 0 |
_tLancet (London, England) _gvol. 387 _gno. 10031 _gp. 1881-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(16)00654-1 _zAvailable from publisher's website |
| 999 |
_c25804661 _d25804661 |
||